Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

In a prior Cancer and Leukemia Group B (CALGB), 16% of a small cohort of patients with extensive small call lung cancer who had failed to obtain a complete remission with chemotherapy did obtain a complete remission after therapy with interleukin-2 (IL-2). In this current trial, 10 patients with extensive small cell lung cancer who had had no prior therapy were treated with subcutaneous IL-2 as induction therapy and then standard chemotherapy with etoposide/cisplatin. Only one patient experienced an objective response to the IL-2 administered prior to chemotherapy. The factors governing response to IL-2 in the first trial but not in this trial are discussed.

Full Text

Duke Authors

Cited Authors

  • Clamon, G; Herndon, J; Akerley, W; Green, M

Published Date

  • January 1998

Published In

Volume / Issue

  • 19 / 1

Start / End Page

  • 25 - 29

PubMed ID

  • 9493137

International Standard Serial Number (ISSN)

  • 0169-5002

Digital Object Identifier (DOI)

  • 10.1016/s0169-5002(97)00070-6


  • eng

Conference Location

  • Ireland